论文部分内容阅读
目的探讨晚期非小细胞肺癌(NSCLC)组织中DNA修复基因家族成员ERCC1、RRM1和BRCA1的表达及其临床意义。方法应用免疫组织化学方法对122例晚期NSCLC组织进行ERCC1、RRM1及BRCA1蛋白表达检测。回顾性分析NSCLC患者的临床特征、化疗反应及预后与肿瘤组织中ERCC1、RRM1和BRCA1蛋白表达的关系。结果 122例晚期NSCLC组织中ERCC1、RRM1和BRCA1蛋白表达阳性率分别为47.5%、35.2%和46.7%。ERCC1和RRM1蛋白表达阳性率与患者的性别、年龄、吸烟状况、体力状况ECOG评分及肿瘤临床分期和组织学类型均无明显相关性(P>0.05);女性患者肿瘤组织BRCA1蛋白表达阳性率(63.6%)显著高于男性患者(40.4%)。ERCC1和BRCA1蛋白表达阳性与阴性患者的化疗有效率、中位生存期和1年生存率比较差异均无统计学意义(P>0.05);RRM1蛋白表达阳性患者的化疗有效率和1年生存率均显著低于RRM1蛋白表达阴性患者(P<0.05)。结论肿瘤组织中RRM1蛋白表达与晚期NSCLC患者的化疗疗效及预后密切相关。
Objective To investigate the expression of ERCC1, RRM1 and BRCA1 in DNA repair gene family and its clinical significance in advanced non-small cell lung cancer (NSCLC). Methods The expression of ERCC1, RRM1 and BRCA1 protein in 122 patients with advanced NSCLC were detected by immunohistochemistry. The clinical features, chemoresistance and prognosis of patients with NSCLC were analyzed retrospectively for the relationship between ERCC1, RRM1 and BRCA1 protein expression. Results The positive rates of ERCC1, RRM1 and BRCA1 in 122 cases of advanced NSCLC were 47.5%, 35.2% and 46.7%, respectively. The positive rate of ERCC1 and RRM1 protein expression had no significant correlation with the gender, age, smoking status, ECOG score, clinical staging and histological type (P> 0.05). The positive rate of BRCA1 protein in female patients 63.6%) were significantly higher than male patients (40.4%). There was no significant difference in the chemotherapy-effective rate, median survival time and 1-year survival rate between ERCC1 and BRCA1 positive and negative patients (P> 0.05). The chemotherapy-effective rate and 1-year survival rate of RRM1 protein positive patients Were significantly lower than those with negative RRM1 protein expression (P <0.05). Conclusion The expression of RRM1 in tumor tissue is closely related to the chemotherapy efficacy and prognosis in patients with advanced NSCLC.